North America holds a notable share of the human rabies immunoglobulin market, driven by high awareness regarding rabies prevention, robust healthcare spending, and established treatment guidelines for post-exposure prophylaxis. The region benefits from strong pharmaceutical manufacturing capabilities, advanced healthcare facilities, and ongoing public health initiatives focused on infectious...

The United States is a key contributor to the inactivated vaccines market, supported by its advanced healthcare infrastructure, strong immunization programs, and significant investments in vaccine research and development. The presence of leading pharmaceutical companies, growing focus on infectious disease prevention, and increasing adoption of adult vaccination programs continue to drive...